CytomX Therapeutics (CTMX) Misses Q3 EPS by 2c

CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $16.92 million versus the consensus estimate of $18.27 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• VNET Group (VNET) Misses Q2 EPS by 164c
• Bernstein on U.S. telecom: "Another strong quarter"